Risankizumab - Psoriatic arthritis

You are here : Home > Formulary Search > Risankizumab - Psoriatic arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Subcutaneous injection (sc)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

ICB

NICE

Restrictions / Comments :

Documentation

Guidelines (Local)

Psoriatic Arthritis High cost immunomodulator drug pathway Apr-24.pdf

Evidence Review

Risankizumab for treating active psoriatic arthritis - NICE briefing paper - September 2022

Webpage

NICE TA803 - Risankizumab for treating psoriatic arthritis - July 2022

PAD Profile

ChemicalSubstance :

Risankizumab

Indication :

Psoriatic arthritis

Group Name :

Keywords :

humanised immunoglobulin G1, IgG1, monoclonal antibody, interleukin (IL)-23 protein, Chinese Hamster Ovary cells, recombinant DNA technology,

Brand Names Include :

Skyrizi

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Risankizumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Psoriatic arthritis.

Committee Recommendations (2)

03 Apr 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated Psoriatic arthritis high cost immunomodulator treatment pathway.

07 Sep 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the use of Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs in line with NICE TA803

Risankizumab will be given a RED traffic light status. Prescribing will be by hospital specialists only, in line with NICE TA803.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.